Pediatric One-Call Center New Patient Referral Form: Fill & Download for Free

The private hospitals in India today are not only equipped with modern state-of-the-art technology but also with highly skilled medical personnel. Indian doctors are considered to be among the best in the world with high level of surgical expertise. These hospitals in India have the range of departments such as surgery care unit, cardiology, emergency care, ICU, chronic treatment unit, radiology, pathology, etc. The private hospitals in India have professional physician, surgeons, and nurses who provide the best treatment and patient care. Due to this Private hospitals in India treats the patients not only from the country but are also are world famous. The best Private hospitals listed here are multi specialty hospitals with trauma centers, hospitals of rehabilitation, children’s hospitals and other departments to meet specific medical needs of the patient. Also these private hospitals in India provide fabulous service to its patients.Top 10 Best Private Hospitals in IndiaThe best private hospitals in India maintain an international standard and has the best medical practitioners, most well-equipped facilities, modern infrastructure and technologically advanced equipment. After being a country that develops quite fast, it is also, improving its health sector.The Moolchand Hospital, New DelhiThe Moolchand Hospital, is one of India’s foremost names in healthcare. They have treated over millions of people over last 50 years. Moolchand is India’s First Hospital to Receive JCI and Comprehensive NABH (Hospital and Blood Bank) Accreditation. This is an 300 bedded hospital with more than 250 super specialities cared by 50+ doctors. The hospital is known for its Key imaging and integrated laboratory services for apt diagnosis of health conditions. This hospital is serving the people for more than five decades now and has excellent treatment options and an exclusive range of upgraded technologies. You can book an appointment online or also call the phone no. given below for appointment.Address: Lajpat Nagar – III, New Delhi, Delhi 110024, IndiaPhone: +91 11 4200 0000Artemis Hospital, GurgaonArtemis Hospital, Is one of the India’s Best Private Hospitals in India. It was established in 2007, is a 380 bed; state-of-the-art multi-speciality hospital located in Gurgaon, India. It is one of the largest hospitals, spread across 9 acres. Artemis Hospital is the first JCI and NABH accredited hospital in Gurgaon. Artemis Hospital provides a depth of expertise in the spectrum of advanced medical & surgical interventions. Top-notch services, in a warm, open centric environment, clubbed with affordability, has made Artemis Hospital one of the most revered hospitals in the country. You could find the preferred doctor and book an appointment online.Address: Sector 51, Wazirabad Village, Gurgaon, Haryana 122001, IndiaPhone: +91 124 676 7000.Tata Memorial Hospital, MumbaiThe Tata Memorial Hospital is one of the top cancer treatment hospital in India. It was initially commissioned by the Sir Dorabji Tata Trust on 28 February 1941. Every year nearly 30,000 new patients visit the clinics from all over India and neighboring countries. Nearly 60% of these cancer patients receive primary care at the Hospital of which over 70% are treated almost free of any charges. Over 1000 patients attend the OPD daily for medical advice, comprehensive care or for follow-up treatment. Supportive care in the form of total rehabilitation, and counselling of patients is widely recognised to be very important aspects of therapy. Excellent work has been carried out in areas of rehabilitation, physiotherapy, occupational therapy, speech therapy, psychology and medical social work.Address: Dr Ernest Borges Rd, Parel, Mumbai, Maharashtra 400012, IndiaPhone: +91 22 2417 7000Lilavati Hospital, MumbaiLilavati Hospital and Research Centre is a premier multi-specialty tertiary care hospital of Mumbai and has been acknowledged globally as centre of medical excellence. It has the state-of-the-art facilities, best medical expertise, research and education. It serves patients from all walks of life – national and international. The hospital is located in the heart of Mumbai; and is very close to the domestic and the international airport.The hospital started functioning in 1997 with 10 beds and initially had only 22 doctors. Today, it boasts of 323 beds with one of the largest Intensive Care Units (ICUs), most advanced 12 Operation Theaters, more than 300 consultants and manpower of nearly 1,800.Hospital attends to around 300 In-patients and 1,500 Out-patients daily. One can find the doctor best suited to them here and book an appointment.Address: A – 791, Bandra Reclamation, Bandra West, Mumbai, Maharashtra 400050, IndiaPhone: +91 22 2675 1000Kokilaben Dhrubai Ambani Hospital, MumbaiKokilaben Dhirubhai Ambani Hospital & Medical Research Institute is one of India’s , most advanced tertiary care facility. It represents a confluence of top-notch talent, cutting-edge technology, state-of-the-art infrastructure. Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute encompassing 10 lakh sq ft of space spread over 17 floors and two basements. It accommodates over 750 inpatient beds and 180 ICU beds. Kokilaben Hospital has a total of over 240 independent consulting clinics, with the capacity to handle over 9,000 outpatient consultations every day. It is also equipped with advance tecnologies like da Vinci Surgical System (Robotic Surgery), IMRIS, Armeo Spring, Radiation Oncology etc.Address: Rao Saheb Achutrao, Patwardhan Marg, Four Bunglows, Andheri West, Mumbai, Maharashtra 400053, IndiaPhone: +91 22 3099 9999.Fortis Malar Hospital, ChennaiFortis Malar Hospital, is one of the best Private hospitals in Chennai. Fortis Malar Hospital is one of the distinguished multi super-specialty corporate hospitals in Chennai providing comprehensive medical care in areas of cardiology, cardio-thoracic surgery, neurology, neurosurgery, orthopedics, nephrology, gynecology, gastroenterology, urology,pediatrics, diabetics and so on. Fortis Malar Hospital has a vast pool of talented and experienced team of doctors, who are further supported by a team of highly qualified, experienced & dedicated support staff & cutting edge technology. Currently, they have more than 160 consultants and 650 employees. They catered to 11000 inpatients in the last year alone. The hospital has around 180 beds including about 60 ICU beds, 4 Operation theaters, state-of-the-art digital flat panel Cath lab, an ultra-modern dialysis unit besides a host of other world-class facilities. One can find the doctor, they think suits them the best online.Address: Fortis Malar Hospital, No. 52, 1st Main Road, Gandhi Nagar, Adyar, Chennai, Tamil Nadu 600020, India.Phone: +91 44 4289 2222.Sri Ganga Ram Hospital, New DelhiSri Ganga Ram Hospital is one of the top hospitals of India. It is an 675 bedded multi-speciality hospital with more than 450 doctors, finest operation theatres, state of the art intensive care units, and high tech laboratories to diagnose and cover most critical health issues. The hospital features Tesla Siemens MRI units with an open bore magnet which is the first of its kind in the country. Owing to its excellent imaging functionalities it serves as a referral base for patients from all over the country and abroad. Its child health services have included organ transplants and emergency pediatric care. The hospital is located in Rajender Nagar, New Delhi. You can check out Sir Ganga Ram Hospital doctors list by clicking on the specific department link. You can find Sir Ganga Ram Hospital consultation charges here.Address: Sir Ganga Ram Hospital Marg, Rajinder Nagar, New Delhi, Delhi 110060, IndiaPhone: +91 11 2575 0000.Medanta Hospital, GurgaonMedanta Hospital is one of the best private hospitals in India. It was established in the year 2009 as a super specialty hospital in Gurgaon city. The hospital is spread in an area of approx 43 acres of land and has around 20 special departments for research and treatment. It has cutting edge technology to treat patients under the observation of highly trained Doctors and nursing staff. It has around 1250 beds and 45 OT to provide treatment to Indian and international patients both. It is famous for its Cardiac Surgeries and is the first hospital in Indian history to perform robotic surgery. Their doctors list is beyond impressive.Address: Golf City, Bagiamau, Lucknow, Uttar Pradesh 226001, India.Phone: +91 87508 08298.Apollo Hospital, ChennaiApollo Hospital is one of the best private hospitals in Chennai. It has created a name for itself in the healthcare sector through cutting-edge innovation in medical procedures and technological advancements. It has over 60 departments, spearheaded by internationally trained and skillful medical experts who are supported by dedicated patient care personnel. They havestate-of-the-art facilities for various health ailments and disorders. They have exceptional clinical success rates and superior technology. Not only could you take physical appointments, but you can also consult doctors online.Address: No. 134, Mint Street, Opposite Ramar Temple, Sowcarpet, Chennai, Tamil Nadu 600079, IndiaPhone: +91 44 2529 6081.Narayana Hrudhalaya, BangaloreThe name Narayana Hrudayalaya is a chain of multi-specialty hospitals in Indian with its headquarteres in Bengaluru. It is oneof the best private hospitals in Bangalore. Narayana Hrudayalaya is India’s most treasured cardiac surgeon and Padma Bhushan awardee Dr. Devi Shetty’s “dream for all”.He established the hospital in Bangalore in 2001 with the view to convey the expensive surgeries affordable to the common people and to offer them a quality health care completely in one place. And now after 15 years of journey, Narayana Hrudayalaya has become destination of Indian as well as thousands of international patients. Narayana Health offers speciality and tertiary care facilities covering a wide range of specialisation viz. cardiac surgery, cardiology,gastroenterology, vascular, endovascular services, nephrology, urology, neurology, nurosurgery, paediatrics, obstetrics & gynaecology, psychiatry, diabetes, endocrinology, cosmetic surgery and rehabilitation, solid organ transplants for kidney, liver, heart and bone marrow transplant as well as general medicine. The group also offers oncology services for most types of cancer including head, neck, breast, cervical, lungs, ortho, uro-genital and gastro intestinal. One can find the doctor they prefer the best and book an appointment online.Address: #258 /A, Narayana Health City, Bommasandra Industrial Area, Anekal Taluk, Hosur Road, Bengaluru, Karnataka 560099, India.Phone: +91 8071 222 222.The Private Hospitals in India are increasingly providing for the healthcare requirements for patients in India and also attracting patients from abroad. Some states are actively promoting this Medical Tourism. So if you are an Indian citizen you should select the best technology and physicians available for the treatment of your dear ones.

Adderall DescriptionA single-entity amphetamine product combining the neutral sulfate salts of dextroamphetamine and amphetamine, with the dextro isomer of amphetamine saccharate and d, l-amphetamine aspartate. kindly email juicetrip at Protonmail dot com to purchase Adderall with and without prescription, not out of context reliable sources and legit.EACH TABLET CONTAINS5 mg7.5 mg10 mg12.5 mg15 mg20 mg30 mgDextroamphetamineSaccharate1.25 mg1.875 mg2.5 mg3.125 mg3.75 mg5 mg7.5 mgAmphetamine Aspartate Monohydrate Equivalent1.25 mg*1.875 mg†2.5 mg‡3.125 mg§3.75 mg¶5 mg#7.5 mgÞDextroamphetamineSulfate, USP1.25 mg1.875 mg2.5 mg3.125 mg3.75 mg5 mg7.5 mgAmphetamineSulfate, USP1.25 mg1.875 mg2.5 mg3.125 mg3.75 mg5 mg7.5 mgTotal Amphetamine Base Equivalence3.13 mg4.7 mg6.3 mg7.8 mg9.4 mg12.6 mg18.8 mgInactive Ingredients: colloidal silicon dioxide, compressible sugar, corn starch, magnesium stearate, microcrystalline cellulose and saccharin sodium.Colors: Adderall ® 5 mg is a white to off-white tablet, which contains no color additives.Adderall ® 7.5 mg and 10 mg contain FD&C Blue #1 Aluminum Lake as a color additive.Adderall ® 12.5 mg, 15 mg, 20 mg and 30 mg contain FD&C Yellow #6 Aluminum Lake as a color additive.Adderall - Clinical PharmacologyPharmacodynamicsAmphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.PharmacokineticsAdderall® tablets contain d-amphetamine and l-amphetamine salts in the ratio of 3:1. Following administration of a single dose 10 or 30 mg of Adderall® to healthy volunteers under fasted conditions, peak plasma concentrations occurred approximately 3 hours post-dose for both d-amphetamine and l-amphetamine. The mean elimination half-life (t1/2) for d-amphetamine was shorter than the t1/2 of the l-isomer (9.77 to 11 hours vs. 11.5 to 13.8 hours). The PK parameters (Cmax, AUC0-inf) of d-and l-amphetamine increased approximately three-fold from 10 mg to 30 mg indicating dose-proportional pharmacokinetics.The effect of food on the bioavailability of Adderall® has not been studied.Metabolism and ExcretionAmphetamine is reported to be oxidized at the 4 position of the benzene ring to form 4-hydroxyamphetamine, or on the side chain α or β carbons to form alpha-hydroxy-amphetamine or norephedrine, respectively. Norephedrine and 4-hydroxy-amphetamine are both active and each is subsequently oxidized to form 4-hydroxy-norephedrine. Alpha-hydroxy-amphetamine undergoes deamination to form phenylacetone, which ultimately forms benzoic acid and its glucuronide and the glycine conjugate hippuric acid. Although the enzymes involved in amphetamine metabolism have not been clearly defined, CYP2D6 is known to be involved with formation of 4-hydroxy-amphetamine. Since CYP2D6 is genetically polymorphic, population variations in amphetamine metabolism are a possibility.Amphetamine is known to inhibit monoamine oxidase, whereas the ability of amphetamine and its metabolites to inhibit various P450 isozymes and other enzymes has not been adequately elucidated. In vitro experiments with human microsomes indicate minor inhibition of CYP2D6 by amphetamine and minor inhibition of CYP1A2, 2D6, and 3A4 by one or more metabolites. However, due to the probability of auto-inhibition and the lack of information on the concentration of these metabolites relative to in vivoconcentrations, no predications regarding the potential for amphetamine or its metabolites to inhibit the metabolism of other drugs by CYP isozymes in vivo can be made.With normal urine pHs approximately half of an administered dose of amphetamine is recoverable in urine as derivatives of alpha-hydroxy-amphetamine and approximately another 30% to 40% of the dose is recoverable in urine as amphetamine itself. Since amphetamine has a pKa of 9.9, urinary recovery of amphetamine is highly dependent on pH and urine flow rates. Alkaline urine pHs result in less ionization and reduced renal elimination, and acidic pHs and high flow rates result in increased renal elimination with clearances greater than glomerular filtration rates, indicating the involvement of active secretion. Urinary recovery of amphetamine has been reported to range from 1% to 75%, depending on urinary pH, with the remaining fraction of the dose hepatically metabolized. Consequently, both hepatic and renal dysfunction have the potential to inhibit the elimination of amphetamine and result in prolonged exposures. In addition, drugs that affect urinary pH are known to alter the elimination of amphetamine, and any decrease in amphetamine’s metabolism that might occur due to drug interactions or genetic polymorphisms is more likely to be clinically significant when renal elimination is decreasedIndications and Usage for AdderallAdderall® (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product)) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy.Attention Deficit Hyperactivity Disorder (ADHD)A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV®) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go;” excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met.Special Diagnostic ConsiderationsSpecific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of the required number of DSM-IV® characteristics.Need for Comprehensive Treatment ProgramAdderall® (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product)) is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the child's symptoms.Long-Term UseThe effectiveness of Adderall®(Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product)) for long-term use has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use Adderall® (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product)) for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.ContraindicationsAdvanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma.Agitated states.Patients with a history of drug abuse.During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result).WarningsSerious Cardiovascular EventsSudden Death and Preexisting Structural Cardiac Abnormalities or Other Serious Heart ProblemsChildren and AdolescentsSudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems.Although some structural heart problems alone may carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drugAdultsSudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD. Although the role of stimulants in these adult cases is also unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems. Adults with such abnormalities should also generally not be treated with stimulant drugsHypertension and Other Cardiovascular ConditionsStimulant medications cause a modest increase in average blood pressure (about 2 to 4 mmHg) and average heart rate (about 3 to 6 bpm) and individuals may have larger increases. While the mean changes alone would not be expected to have short-term consequences, all patients should be monitored for larger changes in heart rate and blood pressure. Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate, e.g., those with preexisting hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmiaAssessing Cardiovascular Status in Patients Being Treated With Stimulant MedicationsChildren, adolescents, or adults who are being considered for treatment with stimulant medications should have a careful history (including assessment for a family history of sudden death or ventricular arrhythmia) and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease (e.g., electrocardiogram and echocardiogram). Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during stimulant treatment should undergo a prompt cardiac evaluation.Psychiatric Adverse EventsPreexisting PsychosisAdministration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with preexisting psychotic disorder.Bipolar IllnessParticular care should be taken in using stimulants to treat ADHD patients with comorbid bipolar disorder because of concern for possible induction of mixed/manic episode in such patients. Prior to initiating treatment with a stimulant, patients with comorbid depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.Emergence of New Psychotic or Manic SymptomsTreatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without prior history of psychotic illness or mania can be caused by stimulants at usual doses. If such symptoms occur, consideration should be given to a possible causal role of the stimulant, and discontinuation of treatment may be appropriate. In a pooled analysis of multiple short-term, placebo-controlled studies, such symptoms occurred in about 0.1% (4 patients with events out of 3482 exposed to methylphenidate or amphetamine for several weeks at usual doses) of stimulant-treated patients compared to 0 in placebo-treated patients.AggressionAggressive behavior or hostility is often observed in children and adolescents with ADHD, and has been reported in clinical trials and the postmarketing experience of some medications indicated for the treatment of ADHD. Although there is no systematic evidence that stimulants cause aggressive behavior or hostility, patients beginning treatment for ADHD should be monitored for the appearance of or worsening of aggressive behavior or hostility.Long-Term Suppression of GrowthCareful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated children over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated children (i.e., treatment for 7 days per week throughout the year) have a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this period of development. Published data are inadequate to determine whether chronic use of amphetamines may cause a similar suppression of growth, however, it is anticipated that they will likely have this effect as well. Therefore, growth should be monitored during treatment with stimulants, and patients who are not growing or gaining weight as expected may need to have their treatment interrupted.SeizuresThere is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizure, in patients with prior EEG abnormalities in absence of seizures, and very rarely, in patients without a history of seizures and no prior EEG evidence of seizures. In the presence of seizures, the drug should be discontinued.Peripheral Vasculopathy, Including Raynaud’s PhenomenonStimulants, including Adderall®, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; however, very rare sequelae include digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud’s phenomenon, were observed in postmarketing reports at different times and at therapeutic doses in all age groups throughout the course of treatment. Signs and symptoms generally improve after reduction in dose or discontinuation of drug. Careful observation for digital changes is necessary during treatment with ADHD stimulants. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.Serotonin SyndromeSerotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John’s Wort .Amphetamines and amphetamine derivatives are known to be metabolized, to some degree, by cytochrome P450 2D6 (CYP2D6) and display minor inhibition of CYP2D6 metabolism . The potential for a pharmacokinetic interaction exists with the coadministration of CYP2D6 inhibitors which may increase the risk with increased exposure to Adderall®. In these situations, consider an alternative non-serotonergic drug or an alternative drug that does not inhibit CYP2D6Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).Concomitant use of Adderall® with MAOI drugs is contraindicatedDiscontinue treatment with Adderall® and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of Adderall® with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate Adderall® with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome.Visual DisturbanceDifficulties with accommodation and blurring of vision have been reported with stimulant treatment.PrecautionsGeneralThe least amount of amphetamine feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. Adderall® should be used with caution in patients who use other sympathomimetic drugs.TicsAmphetamines have been reported to exacerbate motor and phonic tics and Tourette’s syndrome. Therefore, clinical evaluation for tics and Tourette’s syndrome in children and their families should precede use of stimulant medications.Information for PatientsAmphetamines may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or vehicles; the patient should therefore be cautioned accordingly.Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with amphetamine or dextroamphetamine and should counsel them in its appropriate use. A patient Medication Guide is available for Adderall®.The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.Circulation Problems in Fingers and Toes [Peripheral Vasculopathy, Including Raynaud’s Phenomenon]Instruct patients beginning treatment with Adderall® about the risk of peripheral vasculopathy, including Raynaud’s phenomenon, and associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change color from pale, to blue, to red.Instruct patients to report to their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes.Instruct patients to call their physician immediately with any signs of unexplained wounds appearing on fingers or toes while taking Adderall®.Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.Drug InteractionsAcidifying AgentsGastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.Urinary Acidifying Agents(ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion. Both groups of agents lower blood levels and efficacy of amphetamines.Adrenergic BlockersAdrenergic blockers are inhibited by amphetamines.Alkalinizing AgentsGastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines. Coadministration of Adderall® and gastrointestinal alkalizing agents, such as antacids, should be avoided. Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion. Both groups of agents increase blood levels and therefore potentiate the actions of amphetamines.Antidepressants, TricyclicAmphetamines may enhance the activity of tricyclic or sympathomimetic agents; d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated.CYP2D6 InhibitorsThe concomitant use of Adderall® and CYP2D6 inhibitors may increase the exposure of Adderall®compared to the use of the drug alone and increase the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome particularly during Adderall® initiation and after a dosage increase. If serotonin syndrome occurs, discontinue Adderall® and the CYP2D6 inhibitor . Examples of CYP2D6 Inhibitors include paroxetine and fluoxetine (also serotonergic drugs), quinidine, ritonavir.Serotonergic DrugsThe concomitant use of Adderall® and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Adderall® initiation or dosage increase. If serotonin syndrome occurs, discontinue Adderall® and the concomitant serotonergic drug(s) . Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John’s Wort.MAO InhibitorsMAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism. This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; this can cause headaches and other signs of hypertensive crisis. A variety of neurological toxic effects and malignant hyperpyrexia can occur, sometimes with fatal results.AntihistaminesAmphetamines may counteract the sedative effect of antihistamines.AntihypertensivesAmphetamines may antagonize the hypotensive effects of antihypertensives.ChlorpromazineChlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.EthosuximideAmphetamines may delay intestinal absorption of ethosuximide.HaloperidolHaloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.Lithium CarbonateThe anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate.MeperidineAmphetamines potentiate the analgesic effect of meperidine.Methenamine TherapyUrinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.NorepinephrineAmphetamines enhance the adrenergic effect of norepinephrine.PhenobarbitalAmphetamines may delay intestinal absorption of phenobarbital; coadministration of phenobarbital may produce a synergistic anticonvulsant action.PhenytoinAmphetamines may delay intestinal absorption of phenytoin; coadministration of phenytoin may produce a synergistic anticonvulsant action.PropoxypheneIn cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.Proton Pump InhibitorsPPIs act on proton pumps by blocking acid production, thereby reducing gastric acidity. When Adderall XR® (20 mg single-dose) was administered concomitantly with the proton pump inhibitor, omeprazole (40 mg once daily for 14 days), the median Tmax of d-amphetamine was decreased by 1.25 hours (from 4 to 2.75 hours), and the median Tmax of l-amphetamine was decreased by 2.5 hours (from 5.5 to 3 hours), compared to Adderall XR® administered alone. The AUC and Cmax of each moiety were unaffected. Therefore, coadministration of Adderall® and proton pump inhibitors should be monitored for changes in clinical effect.Veratrum AlkaloidsAmphetamines inhibit the hypotensive effect of veratrum alkaloids.Drug/Laboratory Test InteractionsAmphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening. Amphetamines may interfere with urinary steroid determinationsCarcinogenesis/Mutagenesis and Impairment of FertilityNo evidence of carcinogenicity was found in studies in which d,l-amphetamine (enantiomer ratio of 1:1) was administered to mice and rats in the diet for 2 years at doses of up to 30 mg/kg/day in male mice, 19 mg/kg/day in female mice, and 5 mg/kg/day in male and female rats. These doses are approximately 2.4, 1.5, and 0.8 times, respectively, the maximum recommended human dose of 30 mg/day [child] on a mg/m2body surface area basis.Amphetamine, in the enantiomer ratio present in Adderall® (immediate-release)(d- to l- ratio of 3:1), was not clastogenic in the mouse bone marrow micronucleus test in vivo and was negative when tested in the E. coli component of the Ames test in vitro. d, l-Amphetamine (1:1 enantiomer ratio) has been reported to produce a positive response in the mouse bone marrow micronucleus test, an equivocal response in the Ames test, and negative responses in the in vitrosister chromatid exchange and chromosomal aberration assays.Amphetamine, in the enantiomer ratio present in Adderall® (immediate-release)(d- to l- ratio of 3:1), did not adversely affect fertility or early embryonic development in the rat at doses of up to 20 mg/kg/day (approximately 5 times the maximum recommended human dose of 30 mg/day on a mg/m2 body surface area basis).PregnancyTeratogenic EffectsPregnancy Category CAmphetamine, in the enantiomer ratio present in Adderall® (d- to l- ratio of 3:1), had no apparent effects on embryofetal morphological development or survival when orally administered to pregnant rats and rabbits throughout the period of organogenesis at doses of up to 6 and 16 mg/kg/day, respectively. These doses are approximately 1.5 and 8 times, respectively, the maximum recommended human dose of 30 mg/day [child] on a mg/m2 body surface area basis. Fetal malformations and death have been reported in mice following parenteral administration of d-amphetamine doses of 50 mg/kg/day (approximately 6 times that of a human dose of 30 mg/day [child] on a mg/m2basis) or greater to pregnant animals. Administration of these doses was also associated with severe maternal toxicity.A number of studies in rodents indicate that prenatal or early postnatal exposure to amphetamine (d- or d,l-), at doses similar to those used clinically, can result in long-term neurochemical and behavioral alterations. Reported behavioral effects include learning and memory deficits, altered locomotor activity, and changes in sexual function.There are no adequate and well-controlled studies in pregnant women. There has been one report of severe congenital bony deformity, tracheo-esophageal fistula, and anal atresia (vater association) in a baby born to a woman who took dextroamphetamine sulfate with lovastatin during the first trimester of pregnancy. Amphetamines should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Nonteratogenic EffectsInfants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight. Also, these infants may experience symptoms of withdrawal as demonstrated by dysphoria, including agitation, and significant lassitude.Usage in Nursing MothersAmphetamines are excreted in human milk. Mothers taking amphetamines should be advised to refrain from nursing.Pediatric UseLong-term effects of amphetamines in children have not been well established. Amphetamines are not recommended for use in children under 3 years of age with Attention Deficit Hyperactivity Disorder described under INDICATION AND USAGEGeriatric UseAdderall® has not been studied in the geriatric population.Adverse ReactionsCardiovascularPalpitations, tachycardia, elevation of blood pressure, sudden death, myocardial infarction. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use.Central Nervous SystemPsychotic episodes at recommended doses, overstimulation, restlessness, irritability, euphoria, dyskinesia, dysphoria, depression, tremor, tics, aggression, anger, logorrhea, dermatillomania.Eye DisordersVision blurred, mydriasis.GastrointestinalDryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances. Anorexia and weight loss may occur as undesirable effects.AllergicUrticaria, rash, hypersensitivity reactions including angioedema and anaphylaxis. Serious skin rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported.EndocrineImpotence, changes in libido, frequent or prolonged erections.SkinAlopecia.MusculoskeletaDrug Abuse and DependenceAdderall® (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product)) is a Schedule II controlled substance.Amphetamines have been extensively abused. Tolerance, extreme psychological dependence, and severe social disability have occurred. There are reports of patients who have increased the dosage to levels many times higher than recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with amphetamines include severe dermatoses, marked insomnia, irritability, hyperactivity, and personality changes. The most severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia.OverdosageIndividual patient response to amphetamines varies widely. Toxic symptoms may occur idiosyncratically at low doses.SymptomsManifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia and rhabdomyolysis.Fatigue and depression usually follow the central stimulation.Cardiovascular effects include arrhythmias, hypertension or hypotension and circulatory collapse.Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma.TreatmentConsult with a Certified Poison Control Center for up to date guidance and advice. Management of acute amphetamine intoxication is largely symptomatic and includes gastric lavage, administration of activated charcoal, administration of a cathartic and sedation. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendation in this regard. Acidification of the urine increases amphetamine excretion, but is believed to increase risk of acute renal failure if myoglobinuria is present. If acute, severe hypertension complicates amphetamine overdosage, administration of intravenous phentolamine has been suggested. However, a gradual drop in blood pressure will usually result when sufficient sedation has been achieved. Chlorpromazine antagonizes the central stimulant effects of amphetamines and can be used to treat amphetamine intoxication.Adderall Dosage and AdministrationRegardless of indication, amphetamines should be administered at the lowest effective dosage, and dosage should be individually adjusted according to the therapeutic needs and response of the patient. Late evening doses should be avoided because of the resulting insomnia.Attention Deficit Hyperactivity DisorderNot recommended for children under 3 years of age. In children from 3 to 5 years of age, start with 2.5 mg daily; daily dosage may be raised in increments of 2.5 mg at weekly intervals until optimal response is obtained.In children 6 years of age and older, start with 5 mg once or twice daily; daily dosage may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. Only in rare cases will it be necessary to exceed a total of 40 mg per day. Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours.Where possible, drug administration should be interrupted occasionally to determine if there is a recurrence of behavioral symptoms sufficient to require continued therapy.NarcolepsyUsual dose 5 mg to 60 mg per day in divided doses, depending on the individual patient response.Narcolepsy seldom occurs in children under 12 years of age; however, when it does, dextroamphetamine sulfate may be used. The suggested initial dose for patients aged 6 to 12 is 5 mg daily; daily dose may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. In patients 12 years of age and older, start with 10 mg daily; daily dosage may be raised in increments of 10 mg at weekly intervals until optimal response is obtained. If bothersome adverse reactions appear (e.g., insomnia or anorexia), dosage should be reduced. Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours.How is Adderall SuppliedAdderall® (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product)) is supplied as follows:5 mg: White to off-white, round, flat-faced beveled edge tablet with four partial bisects debossed with 5 on one side and debossed with dp on the other side. They are available in bottles of 100 tablets (NDC 57844-105-01).7.5 mg: Blue, oval, biconvex tablet with two partial bisects debossed with 7.5 on one side and one full bisect and two partial bisects debossed with d | p on the other side. They are available in bottles of 100 tablets (NDC 57844-117-01).10 mg: Blue, round, biconvex tablet with one full bisect and two partial bisects debossed with 1 | 0 on one side and debossed with dp on the other side. They are available in bottles of 100 tablets (NDC 57844-110-01).12.5 mg: Peach, round, flat-faced beveled edge tablet debossed with 12.5 on one side and one full bisect and two partial bisects debossed with d | p on the other side. They are available in bottles of 100 tablets (NDC 57844-112-01).15 mg: Peach, oval, biconvex tablet with two partial bisects debossed with 15 on one side and one full bisect and two partial bisects debossed with d | p on the other side. They are available in bottles of 100 tablets (NDC 57844-115-01).20 mg: Peach, round, biconvex tablet with one full bisect and two partial bisects debossed with 2 | 0 on one side and debossed with dp on the other side. They are available in bottles of 100 tablets (NDC 57844-120-01).30 mg: Peach, round, flat-faced beveled edge tablet with one full bisect and 2 partial bisects debossed with 3 | 0 on one side and dp on the other side. They are available in bottles of 100 tablets (NDC 57844-130-01).Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.All brand names listed are the registered trademarks of their respective owners and are not trademarks of Teva Pharmaceuticals USA.Distributed by:Teva Pharmaceuticals USA, Inc.Parsippany, NJ 07054Rev. I 3/2020MEDICATION GUIDEAdderall® (ADD-ur-all) (CII)(Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product))Read the Medication Guide that comes with Adderall® before you or your child starts taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about you or your child’s treatment with Adderall®.What is the most important information I should know about Adderall®?The following have been reported with use of Adderall® and other stimulant medicines.1. Heart-Related Problems:• sudden death in patients who have heart problems or heart defects• stroke and heart attack in adults• increased blood pressure and heart rateTell your doctor if you or your child have any heart problems, heart defects, high blood pressure, or a family history of these problems.Your doctor should check you or your child carefully for heart problems before starting Adderall®.Your doctor should check your or your child’s blood pressure and heart rate regularly during treatment with Adderall®.Call your doctor right away if you or your child have any signs of heart problems such as chest pain, shortness of breath, or fainting while taking Adderall®.2. Mental (Psychiatric) Problems:All Patients• new or worse behavior and thought problems• new or worse bipolar illness• new or worse aggressive behavior or hostilityChildren and Teenagers• new psychotic symptoms (such as hearing voices, believing things that are not true, are suspicious) or new manic symptomsTell your doctor about any mental problems you or your child have, or about a family history of suicide, bipolar illness, or depression.Call your doctor right away if you or your child have any new or worsening mental symptoms or problems while taking Adderall®, especially seeing or hearing things that are not real, believing things that are not real, or are suspicious.3. Circulation Problems in Fingers and Toes [Peripheral Vasculopathy, Including Raynaud’s Phenomenon]:Fingers or toes may feel numb, cool, painfulFingers or toes may change color from pale, to blue, to redTell your doctor if you have or your child has numbness, pain, skin color change, or sensitivity to temperature in your fingers or toes.Call your doctor right away if you have or your child has any signs of unexplained wounds appearing on fingers or toes while taking Adderall®.What is Adderall®?Adderall® is a central nervous system stimulant prescription medicine. It is used for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). Adderall® may help increase attention and decrease impulsiveness and hyperactivity in patients with ADHD.Adderall® should be used as a part of a total treatment program for ADHD that may include counseling or other therapies.Adderall® is also used in the treatment of a sleep disorder called narcolepsy.Adderall® is a federally controlled substance (CII) because it can be abused or lead to dependence. Keep Adderall® in a safe place to prevent misuse and abuse. Selling or giving away Adderall® may harm others, and is against the law.Tell your doctor if you or your child have (or have a family history of) ever abused or been dependent on alcohol, prescription medicines or street drugs.Who should not take Adderall®?Adderall® should not be taken if you or your child:have heart disease or hardening of the arterieshave moderate to severe high blood pressurehave hyperthyroidismhave an eye problem called glaucomaare very anxious, tense, or agitatedhave a history of drug abuseare taking or have taken within the past 14 days an anti-depression medicine called a monoamine oxidase inhibitor or MAOI.are sensitive to, allergic to, or had a reaction to other stimulant medicinesAdderall® is not recommended for use in children less than 3 years old.Adderall® may not be right for you or your child. Before starting Adderall® tell your or your child’s doctor about all health conditions (or a family history of) including:heart problems, heart defects, high blood pressuremental problems including psychosis, mania, bipolar illness, or depressiontics or Tourette’s syndromeliver or kidney problemscirculation problems in fingers and toesthyroid problemsseizures or have had an abnormal brain wave test (EEG)Tell your doctor if you or your child are pregnant, planning to become pregnant, or breastfeeding.Can Adderall® be taken with other medicines?Tell your doctor about all of the medicines that you or your child take including prescription and nonprescription medicines, vitamins, and herbal supplements. Adderall® and some medicines may interact with each other and cause serious side effects. Sometimes the doses of other medicines will need to be adjusted while taking Adderall®.Your doctor will decide whether Adderall® can be taken with other medicines.Especially tell your doctor if you or your child take:anti-depression medicines including MAOIsblood pressure medicinesseizure medicinesblood thinner medicinescold or allergy medicines that contain decongestantsstomach acid medicinesKnow the medicines that you or your child take. Keep a list of your medicines with you to show your doctor and pharmacist.Do not start any new medicine while taking Adderall® without talking to your doctor first.How should Adderall® be taken?Take Adderall® exactly as prescribed. Your doctor may adjust the dose until it is right for you or your child.Adderall® tablets are usually taken two to three times a day. The first dose is usually taken when you first wake in the morning. One or two more doses may be taken during the day, 4 to 6 hours apart.Adderall® can be taken with or without food.From time to time, your doctor may stop Adderall® treatment for a while to check ADHD symptoms.Your doctor may do regular checks of the blood, heart, and blood pressure while taking Adderall®. Children should have their height and weight checked often while taking Adderall®. Adderall® treatment may be stopped if a problem is found during these check-ups.If you or your child take too much Adderall®or overdose, call your doctor or poison control center right away, or get emergency treatment.What are possible side effects of Adderall®?See “What is the most important information I should know about Adderall®?” for information on reported heart and mental problems.Other serious side effects include:slowing of growth (height and weight) in childrenseizures, mainly in patients with a history of seizureseyesight changes or blurred visionserotonin syndrome. A potentially life-threatening problem called serotonin syndrome can happen when medicines such as Adderall® are taken with certain other medicines. Symptoms of serotonin syndrome may include:agitation, hallucinations, coma or other changes in mental statusproblems controlling your movements or muscle twitchingfast heartbeathigh or low blood pressuresweating or fevernausea or vomitingdiarrheamuscle stiffness or tightnessCommon side effects include:stomach achedecreased appetitenervousnessAdderall® may affect your or your child’s ability to drive or do other dangerous activities.Talk to your doctor if you or your child have side effects that are bothersome or do not go away.This is not a complete list of possible side effects. Ask your doctor or pharmacist for more information.How should I store Adderall®?Store Adderall® in a safe place at room temperature, 20° to 25°C (68° to 77°F).Keep Adderall® and all medicines out of the reach of children.General information about Adderall®Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Adderall® for a condition for which it was not prescribed. Do not give Adderall®to other people, even if they have the same condition. It may harm them and it is against the law. This Medication Guide summarizes the most important information about Adderall®. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about Adderall® that was written for healthcare professionals.What are the ingredients in Adderall®?Active Ingredient: dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate.Inactive Ingredients: colloidal silicon dioxide, compressible sugar, corn starch, magnesium stearate, microcrystalline cellulose and saccharin sodium. The 5 mg is a white to off-white tablet, which contains no color additives. The 7.5 mg and 10 mg also contain FD&C Blue #1 Aluminum Lake as a color additive. The 12.5 mg, 15 mg, 20 mg and 30 mg also contain FD&C Yellow #6 Aluminum Lake as a color additive.This Medication Guide has been approved by the U.S. Food and Drug Administration.Distributed by:Teva Pharmaceuticals USA, Inc.Parsippany, NJ 07054Rev. H 3/2020Package/Label Display PanelAdderall® 5 mg CII 100s Label TextNDC 57844-105-01CIIAdderall®(Dextroamphetamine Saccharate,Amphetamine Aspartate,Dextroamphetamine Sulfate andAmphetamine Sulfate Tablets)(Mixed Salts of a Single EntityAmphetamine Product)5 mgPHARMACIST: DISPENSE THEACCOMPANYING MEDICATIONGUIDE TO EACH PATIENT.Rx only100 TABLETSTEVAPackage/Label Display PanelAdderall® 7.5 mg CII 100s Label TextNDC 57844-117-01CIIAdderall®(Dextroamphetamine Saccharate,Amphetamine Aspartate,Dextroamphetamine Sulfate andAmphetamine Sulfate Tablets)(Mixed Salts of a Single EntityAmphetamine Product)7.5 mgPHARMACIST: DISPENSE THEACCOMPANYING MEDICATIONGUIDE TO EACH PATIENT.Rx only100 TABLETSTEVAPackage/Label Display PanelAdderall® 10 mg CII 100s Label TextNDC 57844-110-01CIIAdderall®(Dextroamphetamine Saccharate,Amphetamine Aspartate,Dextroamphetamine Sulfate andAmphetamine Sulfate Tablets)(Mixed Salts of a Single EntityAmphetamine Product)10 mgPHARMACIST: DISPENSE THEACCOMPANYING MEDICATIONGUIDE TO EACH PATIENT.Rx only100 TABLETSTEVAPackage/Label Display PanelAdderall® 12.5 mg CII 100s Label TextNDC 57844-112-01CIIAdderall®(Dextroamphetamine Saccharate,Amphetamine Aspartate,Dextroamphetamine Sulfate andAmphetamine Sulfate Tablets)(Mixed Salts of a Single EntityAmphetamine Product)12.5 mgPHARMACIST: DISPENSE THEACCOMPANYING MEDICATIONGUIDE TO EACH PATIENT.Rx only100 TABLETSTEVAPackage/Label Display PanelAdderall® 15 mg CII 100s Label TextNDC 57844-115-01CIIAdderall®(Dextroamphetamine Saccharate,Amphetamine Aspartate,Dextroamphetamine Sulfate andAmphetamine Sulfate Tablets)(Mixed Salts of a Single EntityAmphetamine Product)15 mgPHARMACIST: DISPENSE THEACCOMPANYING MEDICATIONGUIDE TO EACH PATIENT.Rx only100 TABLETSTEVAPackage/Label Display PanelAdderall® 20 mg CII 100s Label TextNDC 57844-120-01CIIAdderall®(Dextroamphetamine Saccharate,Amphetamine Aspartate,Dextroamphetamine Sulfate andAmphetamine Sulfate Tablets)(Mixed Salts of a Single EntityAmphetamine Product)20 mgPHARMACIST: DISPENSE THEACCOMPANYING MEDICATIONGUIDE TO EACH PATIENT.Rx only100 TABLETSTEVAPackage/Label Display PanelAdderall® 30 mg CII 100s Label TextNDC 57844-130-01CIIAdderall®(Dextroamphetamine Saccharate,Amphetamine Aspartate,Dextroamphetamine Sulfate andAmphetamine Sulfate Tablets)(Mixed Salts of a Single EntityAmphetamine Product)30 mgPHARMACIST: DISPENSE THEACCOMPANYING MEDICATIONGUIDE TO EACH PATIENT.Rx only100 TABLETSTEVAAdderalldextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tabletProduct InformationProduct TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:57844-105Route of AdministrationORALDEA ScheduleCIIActive Ingredient/Active MoietyIngredient NameBasis of StrengthStrengthDEXTROAMPHETAMINE SACCHARATE(DEXTROAMPHETAMINE)DEXTROAMPHETAMINE SACCHARATE1.25 mgAMPHETAMINE ASPARTATE MONOHYDRATE(AMPHETAMINE)AMPHETAMINE ASPARTATE MONOHYDRATE1.25 mgDEXTROAMPHETAMINE SULFATE(DEXTROAMPHETAMINE)DEXTROAMPHETAMINE SULFATE1.25 mgAMPHETAMINE SULFATE(AMPHETAMINE)AMPHETAMINE SULFATE1.25 mgInactive IngredientsIngredient NameStrengthSILICON DIOXIDESUCROSEMALTODEXTRINSTARCH, CORNMAGNESIUM STEARATECELLULOSE, MICROCRYSTALLINESACCHARIN SODIUMProduct CharacteristicsColorWHITE (white to off-white)Score4 piecesShapeROUNDSize7mmFlavorImprint Code5;dpContainsPackaging#Item CodePackage Description1NDC:57844-105-01100 TABLET in 1 BOTTLEMarketing InformationMarketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End DateANDAANDA04042211/13/2014Adderalldextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tabletProduct InformationProduct TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:57844-117Route of AdministrationORALDEA ScheduleCIIActive Ingredient/Active MoietyIngredient NameBasis of StrengthStrengthDEXTROAMPHETAMINE SACCHARATE(DEXTROAMPHETAMINE)DEXTROAMPHETAMINE SACCHARATE1.875 mgAMPHETAMINE ASPARTATE MONOHYDRATE(AMPHETAMINE)AMPHETAMINE ASPARTATE MONOHYDRATE1.875 mgDEXTROAMPHETAMINE SULFATE(DEXTROAMPHETAMINE)DEXTROAMPHETAMINE SULFATE1.875 mgAMPHETAMINE SULFATE(AMPHETAMINE)AMPHETAMINE SULFATE1.875 mgInactive IngredientsIngredient NameStrengthSILICON DIOXIDESUCROSEMALTODEXTRINSTARCH, CORNMAGNESIUM STEARATECELLULOSE, MICROCRYSTALLINESACCHARIN SODIUMFD&C BLUE NO. 1 ALUMINUM LAKEProduct CharacteristicsColorBLUEScore4 piecesShapeOVALSize10mmFlavorImprint Code7;5;d;pContainsPackaging#Item CodePackage Description1NDC:57844-117-01100 TABLET in 1 BOTTLEMarketing InformationMarketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End DateANDAANDA04042203/03/2015Adderalldextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tabletProduct InformationProduct TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:57844-110Route of AdministrationORALDEA ScheduleCIIActive Ingredient/Active MoietyIngredient NameBasis of StrengthStrengthDEXTROAMPHETAMINE SACCHARATE(DEXTROAMPHETAMINE)DEXTROAMPHETAMINE SACCHARATE2.5 mgAMPHETAMINE ASPARTATE MONOHYDRATE(AMPHETAMINE)AMPHETAMINE ASPARTATE MONOHYDRATE2.5 mgDEXTROAMPHETAMINE SULFATE(DEXTROAMPHETAMINE)DEXTROAMPHETAMINE SULFATE2.5 mgAMPHETAMINE SULFATE(AMPHETAMINE)AMPHETAMINE SULFATE2.5 mgInactive IngredientsIngredient NameStrengthSILICON DIOXIDESUCROSEMALTODEXTRINSTARCH, CORNMAGNESIUM STEARATECELLULOSE, MICROCRYSTALLINESACCHARIN SODIUMFD&C BLUE NO. 1 ALUMINUM LAKEProduct CharacteristicsColorBLUEScore4 piecesShapeROUNDSize9mmFlavorImprint Code1;0;dpContainsPackaging#Item CodePackage Description1NDC:57844-110-01100 TABLET in 1 BOTTLEMarketing InformationMarketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End DateANDAANDA04042202/03/2014Adderalldextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tabletProduct InformationProduct TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:57844-112Route of AdministrationORALDEA ScheduleCIIActive Ingredient/Active MoietyIngredient NameBasis of StrengthStrengthDEXTROAMPHETAMINE SACCHARATE(DEXTROAMPHETAMINE)DEXTROAMPHETAMINE SACCHARATE3.125 mgAMPHETAMINE ASPARTATE MONOHYDRATE(AMPHETAMINE)AMPHETAMINE ASPARTATE MONOHYDRATE3.125 mgDEXTROAMPHETAMINE SULFATE(DEXTROAMPHETAMINE)DEXTROAMPHETAMINE SULFATE3.125 mgAMPHETAMINE SULFATE(AMPHETAMINE)AMPHETAMINE SULFATE3.125 mgInactive IngredientsIngredient NameStrengthSILICON DIOXIDESUCROSEMALTODEXTRINSTARCH, CORNMAGNESIUM STEARATECELLULOSE, MICROCRYSTALLINESACCHARIN SODIUMFD&C YELLOW NO. 6Product CharacteristicsColorORANGE (peach)Score4 piecesShapeROUNDSize7mmFlavorImprint Code12;5;d;pContainsPackaging#Item CodePackage Description1NDC:57844-112-01100 TABLET in 1 BOTTLEMarketing InformationMarketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End DateANDAANDA04042206/18/2014Adderalldextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tabletProduct InformationProduct TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:57844-115Route of AdministrationORALDEA ScheduleCIIActive Ingredient/Active MoietyIngredient NameBasis of StrengthStrengthDEXTROAMPHETAMINE SACCHARATE(DEXTROAMPHETAMINE)DEXTROAMPHETAMINE SACCHARATE3.75 mgAMPHETAMINE ASPARTATE MONOHYDRATE(AMPHETAMINE)AMPHETAMINE ASPARTATE MONOHYDRATE3.75 mgDEXTROAMPHETAMINE SULFATE(DEXTROAMPHETAMINE)DEXTROAMPHETAMINE SULFATE3.75 mgAMPHETAMINE SULFATE(AMPHETAMINE)AMPHETAMINE SULFATE3.75 mgInactive IngredientsIngredient NameStrengthSILICON DIOXIDESUCROSEMALTODEXTRINSTARCH, CORNMAGNESIUM STEARATECELLULOSE, MICROCRYSTALLINESACCHARIN SODIUMFD&C YELLOW NO. 6Product CharacteristicsColorORANGE (peach)Score4 piecesShapeOVALSize10mmFlavorImprint Code15;d;pContainsPackaging#Item CodePackage Description1NDC:57844-115-01100 TABLET in 1 BOTTLEMarketing InformationMarketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End DateANDAANDA04042206/30/2014Adderalldextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tabletProduct InformationProduct TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:57844-120Route of AdministrationORALDEA ScheduleCIIActive Ingredient/Active MoietyIngredient NameBasis of StrengthStrengthDEXTROAMPHETAMINE SACCHARATE(DEXTROAMPHETAMINE)DEXTROAMPHETAMINE SACCHARATE5 mgAMPHETAMINE ASPARTATE MONOHYDRATE(AMPHETAMINE)AMPHETAMINE ASPARTATE MONOHYDRATE5 mgDEXTROAMPHETAMINE SULFATE(DEXTROAMPHETAMINE)DEXTROAMPHETAMINE SULFATE5 mgAMPHETAMINE SULFATE(AMPHETAMINE)AMPHETAMINE SULFATE5 mgInactive IngredientsIngredient NameStrengthSILICON DIOXIDESUCROSEMALTODEXTRINSTARCH, CORNMAGNESIUM STEARATECELLULOSE, MICROCRYSTALLINESACCHARIN SODIUMFD&C YELLOW NO. 6Product CharacteristicsColorORANGE (peach)Score4 piecesShapeROUNDSize9mmFlavorImprint Code2;0;dpContainsPackaging#Item CodePackage Description1NDC:57844-120-01100 TABLET in 1 BOTTLEMarketing InformationMarketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End DateANDAANDA04042202/11/2014Adderalldextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tabletProduct InformationProduct TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:57844-130Route of AdministrationORALDEA ScheduleCIIActive Ingredient/Active MoietyIngredient NameBasis of StrengthStrengthDEXTROAMPHETAMINE SACCHARATE(DEXTROAMPHETAMINE)DEXTROAMPHETAMINE SACCHARATE7.5 mgAMPHETAMINE ASPARTATE MONOHYDRATE(AMPHETAMINE)AMPHETAMINE ASPARTATE MONOHYDRATE7.5 mgDEXTROAMPHETAMINE SULFATE(DEXTROAMPHETAMINE)DEXTROAMPHETAMINE SULFATE7.5 mgAMPHETAMINE SULFATE(AMPHETAMINE)AMPHETAMINE SULFATE7.5 mgInactive IngredientsIngredient NameStrengthSILICON DIOXIDESUCROSEMALTODEXTRINSTARCH, CORNMAGNESIUM STEARATECELLULOSE, MICROCRYSTALLINESACCHARIN SODIUMFD&C YELLOW NO. 6Product CharacteristicsColorORANGE (peach)Score4 piecesShapeROUNDSize10mmFlavorImprint Code3;0;dpContainsPackaging#Item CodePackage Description1NDC:57844-130-01100 TABLET in 1 BOTTLE

I can’t speak to suing the parents. I’m not sure how that would work.But you can sue the facility which performed it on you and perhaps file a complaint against the practitioners. It’s been filed against in the following ways so there are precedents set. (I know this is a lot of information, but it’s ammunition for your attorney). I hope this helps.In August of 2013, the 9th U.S. Circuit Court of Appeals upheld California’s law, which was signed by Democratic Governor Jerry Brown in 2012. In May of 2015 and again in February of 2016, the United States Supreme Court let stand decisions of the 3rd U.S. Circuit Court of Appeals upholding New Jersey’s law, which was signed by Republican Governor Chris Christie in August of 2013. In February of 2015, a NJ Superior Court judge ruled that misrepresenting homosexuality as a disorder violates the state’s consumer protection laws. Additionally, in June of 2015, the jury in that case found a conversion therapy provider liable for consumer fraud and ordered the provider to pay the plaintiffs for refunds and damages.In February 2016, the Human Rights Campaign, National Center for Lesbian Rights, and Southern Poverty Law Center filed a consumer fraud complaint with the Federal Trade Commission (FTC) against People Can Change, a major provider of conversion therapy. The complaint alleges that People Can Change’s advertisements and business practices which claim they can change a person’s sexual orientation or gender identity constitute deceptive, false, and misleading practices and can cause serious harm to consumers, all in direct violation of Section 5 of the Federal Trade Commission Act. The complaint urges the FTC to take enforcement action to stop these deceptive practices and investigate all practitioners making similar claims.Most of the mental health organizations overseeing the ethics and licensing of mental health professionals have stated, unequivocally, this is not a valid form of therapy. So any mental health professional practicing it after those statements were made is committing at least an ethics violation and should have a complaint filed upon their license. A lot of these positions were made in the 1990s. I’ve posted these statements below.The problem will be if the “therapy” was provided by someone who is unlicensed. We see this a lot with pastoral care where a leader or member of a church is providing “therapy” guided by the teachings of that religion. No one has any governance over them so they can pretty much do what they want if they don’t break any laws. If that’s the case you won’t be able to file a complaint with their governing board because there isn’t one.But back to licensed therapists. The list of positions is below. In the United States these are the licenses which are most often found and the association which governs their ethics:American Association for Marriage and Family Therapy which governs LMFTs (licensed marriage and family therapists)American Counseling Association which governs LPCs (licensed professional counselors)American Psychiatric Association which governs psychiatrists (M.D.s)American Psychological Association which governs psychologists (Ph.D.s)National Association of Social Workers which governs LCSWs (social workers).Organizational Positions on Reparative TherapyAmerican Academy of Child Adolescent Psychiatry"The American Academy of Child and Adolescent Psychiatry finds no evidence to support the application of any “therapeutic intervention” operating under the premise that a specific sexual orientation, gender identity, and/or gender expression is pathological. Furthermore, based on the scientific evidence, the AACAP asserts that such “conversion therapies” (or other interventions imposed with the intent of promoting a particular sexual orientation and/or gender as a preferred outcome) lack scientific credibility and clinical utility. Additionally, there is evidence that such interventions are harmful. As a result, “conversion therapies” should not be part of any behavioral health treatment of children and adolescents."The AACAP Policy on “Conversion Therapies”.American Academy of Pediatrics"Confusion about sexual orientation is not unusual during adolescence. Counseling may be helpful for young people who are uncertain about their sexual orientation or for those who are uncertain about how to express their sexuality and might profit from an attempt at clarification through a counseling or psychotherapeutic initiative. Therapy directed specifically at changing sexual orientation is contraindicated, since it can provoke guilt and anxiety while having little or no potential for achieving changes in orientation."Homosexuality and Adolescence, Pediatrics.American Association for Marriage and Family Therapy"[T]he association does not consider homosexuality a disorder that requires treatment, and as such, we see no basis for [reparative therapy]. AAMFT expects its members to practice based on the best research and clinical evidence available."AAMFT Position on Couples and Families.American College of Physicians"The College opposes the use of “conversion,” “reorientation,” or “reparative” therapy for the treatment of LGBTQ persons."Lesbian, Gay, Bisexual, and Transgender Health Disparities: Executive Summary of a Policy Position Paper From the American College of PhysiciansAmerican Counseling Association“The belief that same-sex attraction and behavior is abnormal and in need of treatment is in opposition to the position taken by national mental health organizations, including ACA. The ACA Governing Council passed a resolution in 1998 with respect to sexual orientation and mental health. This resolution specifically notes that ACA opposes portrayals of lesbian, gay and bisexual individuals as mentally ill due to their sexual orientation. . . . In 1999, the Governing Council adopted a statement ‘opposing the promotion of reparative therapy as a cure for individuals who are homosexual.’ . . .[T]he ACA Ethics Committee strongly suggests that ethical professional counselors do not refer clients to someone who engages in conversion therapy or, if they do so, to proceed cautiously only when they are certain that the referral counselor fully informs clients of the unproven nature of the treatment and the potential risks and takes steps to minimize harm to clients. . . . This information also must be included in written informed consent material by those counselors who offer conversion therapy despite ACA’s position and the Ethics Committee’s statement in opposition to the treatment. To do otherwise violates the spirit and specifics of the ACA Code of Ethics.”Ethical Issues Related to Conversion or Reparative Therapy.American Medical Association"Our AMA… opposes, the use of 'reparative' or 'conversion' therapy that is based upon the assumption that homosexuality per se is a mental disorder or based upon the a priori assumption that the patient should change his/her homosexual orientation."H-160.991, Health Care Needs of the Homosexual Population.American Psychiatric Association... In 1997 APA produced a fact sheet on homosexual and bisexual issues, which states that “there is no published scientific evidence supporting the efficacy of “reparative therapy” as a treatment to change one’s sexual orientation.”The potential risks of “reparative therapy” are great and include depression, anxiety, and self-destructive behavior, since therapist alignment with societal prejudices against homosexuality may reinforce self-hatred already experienced by the patient. Many patients who have undergone “reparative therapy” relate that they were inaccurately told that homosexuals are lonely, unhappy individuals who never achieve acceptance or satisfaction. The possibility that the person might achieve happiness and satisfying interpersonal relationships as a gay man or lesbian are not presented, nor are alternative approaches to dealing with the effects of societal stigmatization discussed...Therefore, APA opposes any psychiatric treatment, such as “reparative” or “conversion” therapy, that is based on the assumption that homosexuality per se is a mental disorder or is based on the a priori assumption that the patient should change his or her homosexual orientation.Position Statement on Psychiatric Treatment and Sexual Orientation).American Psychoanalytic Association“As with any societal prejudice, bias against individuals based on actual or perceived sexual orientation, gender identity or gender expression negatively affects mental health, contributing to an enduring sense of stigma and pervasive self-criticism through the internalization of such prejudice.Psychoanalytic technique does not encompass purposeful attempts to ‘convert,’ “repair,” change or shift an individual’s sexual orientation, gender identity or gender expression. Such directed efforts are against fundamental principles of psychoanalytic treatment and often result in substantial psychological pain by reinforcing damaging internalized attitudes.”Position Statement on Attempts to Change Sexual Orientation, Gender Identity, or Gender Expression.American Psychological Association"THEREFORE, BE IT RESOLVED, That the American Psychological Association affirms that same-sex sexual and romantic attractions, feelings, and behaviors are normal and positive variations of human sexuality regardless of sexual orientation identity;BE IT FURTHER RESOLVED, That the American Psychological Association reaffirms its position that homosexuality per se is not a mental disorder and opposes portrayals of sexual minority youths and adults as mentally ill due to their sexual orientation;BE IT FURTHER RESOLVED, That the American Psychological Association concludes that there is insufficient evidence to support the use of psychological interventions to change sexual orientation;BE IT FURTHER RESOLVED, That the American Psychological Association encourages mental health professionals to avoid misrepresenting the efficacy of sexual orientation change efforts by promoting or promising change in sexual orientation when providing assistance to individuals distressed by their own or others' sexual orientation…"Resolution on Appropriate Affirmative Responses to Sexual Orientation Distress and Change Efforts.American School Counselor Association"Lesbian, gay, bisexual, transgendered and questioning (LGBTQ) youth often begin to experience self-identification during their pre-adolescent or adolescent years, as do heterosexual youth. These developmental processes are essential cognitive, emotional and social activities, and although they may have an impact on student development and achievement, they are not a sign of illness, mental disorder or emotional problems nor do they necessarily signify sexual activity.The professional school counselor works with all students through the stages of identity development and understands this development may be more difficult for LGBTQ youth. It is not the role of the professional school counselor to attempt to change a student's sexual orientation/gender identity but instead to provide support to LGBTQ students to promote student achievement and personal well-being."The Professional School Counselor and LGBTQ Youth.American School Health Association“[T]he American School Health Association . . . expects that comprehensive sexuality education in schools will be scientifically accurate and based on current medical, psychological, pedagogical, educational and social research . . . [and recommends] that teachers be well-trained and competent to teach sexuality education as defined by . . . insight into and acceptance of their own personal feelings and attitudes concerning sexuality topics so personal life experiences do not intrude inappropriately into the educational experience.”Quality Comprehensive Sexuality Education.National Association of Social Workers"People seek mental health services for many reasons. Accordingly, it is fair to assert that lesbians and gay men seek therapy for the same reasons that heterosexual people do. However, the increase in media campaigns, often coupled with coercive messages from family and community members, has created an environment in which lesbians and gay men often are pressured to seek reparative or conversion therapies, which cannot and will not change sexual orientation. Aligned with the American Psychological Association's (1997) position, NCLGB [NASW's National Committee on Lesbian and Gay Issues] believes that such treatment potentially can lead to severe emotional damage. Specifically, transformational ministries are fueled by stigmatization of lesbians and gay men, which in turn produces the social climate that pressures some people to seek change in sexual orientation. No data demonstrate that reparative or conversion therapies are effective, and in fact they may be harmful."Position Statement, "Reparative" and "Conversion" Therapies.Pan American Health Organization (PAHO): Regional Office of the World Health OrganizationServices that purport to "cure" people with non-heterosexual sexual orientation lack medical justification and represent a serious threat to the health and well-being of affected people, the Pan American Health Organization (PAHO) said in a position statement launched on 17 May, 2012, the International Day against Homophobia. The statement calls on governments, academic institutions, professional associations and the media to expose these practices and to promote respect for diversity.Statement, "Therapies" to change sexual orientation lack medical justification and threaten health.Just the Facts Coalition (American Academy of Pediatrics, American Association of School Administrators, American Counseling Association, American Federation of Teachers, American Psychological Association, American School Counselor Association, American School Health Association, Interfaith Alliance Foundation, National Association of School Psychologists, National Association of Secondary School Principals, National Association of Social Workers, national Education Association, School Social Work Association of America)“The most important fact about 'reparative therapy,' also sometimes known as 'conversion' therapy, is that it is based on an understanding of homosexuality that has been rejected by all the major health and mental health professions. The American Academy of Pediatrics, the American Counseling Association, the American Psychiatric Association, the American Psychological Association, the National Association of School Psychologists, and the National Association of Social Workers, together representing more than 477,000 health and mental health professionals, have all taken the position that homosexuality is not a mental disorder and thus there is no need for a 'cure.'”Just the Facts About Sexual Orientation and Youth: A Primer for Principals, Educators, and School Personnel.World Psychiatric Association“There is no sound scientific evidence that innate sexual orientation can be changed. Furthermore, so-called treatments of homosexuality can create a setting in which prejudice and discrimination flourish, and they can be potentially harmful (Rao and Jacob 2012). The provision of any intervention purporting to “treat” something that is not a disorder is wholly unethical.….WPA considers same-sex attraction, orientation, and behaviour as normal variants of human sexuality. It recognises the multi-factorial causation of human sexuality, orientation, behaviour, and lifestyle. It acknowledges the lack of scientific efficacy of treatments that attempt to change sexual orientation and highlights the harm and adverse effects of such “therapies”.”WPA Position Statement on Gender Identity and Same-Sex Orientation, Attraction, and Behaviours